Alvotech Revenue Dips 2% on Lower License Income

The biosimilar drugmaker's third-quarter results show product sales growth offset by a sharp drop in licensing revenue.

Updated on Nov. 12, 2026 in Biotech

Alvotech Revenue Dips 2% on Lower License Income

Alvotech reported third-quarter revenue of $111.6 million, down 2% from a year earlier. Product and service revenue rose 78.3% to $58.2 million, while license and other revenue fell 34.4% to $53.2 million.

Why it matters

The results show a shift in Alvotech's revenue mix toward product sales as licensing income declines. Investors and partners will be watching whether this mix change supports margins going forward.

Alvotech's adjusted EBITDA more than doubled to $31.5 million from $14.4 million, even as gross margin narrowed from 69% to 54%. The company has not said what portion of the margin compression reflects its shift toward lower-margin product sales.

The players

Alvotech

Alvotech is an Icelandic biopharmaceutical company that develops and manufactures biosimilar medicines for global markets.

The details

Product and service revenue grew 78.3% to $58.2 million, while license and other revenue dropped 34.4% to $53.2 million. Alvotech maintained its 2026 guidance and expects total revenue and EBITDA to land near the lower ends of their ranges.

Timeline

  1. Third quarter 2026: Alvotech reports $111.6 million in revenue, down 2% year over year.

  2. Fourth quarter 2026: Planned product shipments are scheduled for delivery.

  3. Full year 2026: Company expects revenue and EBITDA near the lower end of guidance.

The Tech Race

Alvotech's results sit within the broader expansion of biosimilar medicines as originator drug patents expire across major markets. The quarter shows product sales gaining ground while licensing deals, which often front-load revenue, contribute less.

For patients and payers, growth in biosimilar product sales can expand access to lower-cost versions of established biologic medicines. The company's guidance signals that revenue and EBITDA may finish near the lower end of expectations this year.

The takeaway

Alvotech's results show that revenue quality matters as much as headline totals, since a shift toward product sales can change margins even when earnings rise. Readers tracking biosimilar companies should watch how licensing income and product margins evolve through the year.

Further reading

For broader context on drug development, explore Biotech coverage.

Source note: This article includes information reported by TokenPost.